FOUNTAIN HILLS, Ariz., Nov. 10 /PRNewswire-FirstCall/ -- Medistem Laboratories, Inc. , a biotechnology company dedicated to development of clinical applications of non-controversial adult stem cells for certain medical conditions, said today that in connection with its name change from SGC Holdings, Inc., Nasdaq has assigned it a new OTC Bulletin Board symbol, MDSM.
Medistem Laboratories has begun trading under the symbol, OTC BB: MDSM, which replaces SGCH. In connection with the new name and symbol, Medistem Laboratories’ common stock has been assigned a new CUSIP No., “58501F 10 8.”
Medistem also reported that the state of Nevada has approved the company’s name change from SGC Holdings, Inc. to Medistem Laboratories, Inc.
“Medistem Laboratories, Inc. more accurately reflects our company’s current and future business activities,” said CEO Neil Riordan, Ph.D.
About Medistem Laboratories, Inc.
Medistem Laboratories’ business is the development of medical treatments using non-controversial adult stem cells. The corporate mission is limited to treatments using adult stem cells derived from muscle, bone marrow or fat of the patient being treated, and adult stem cells generated from full-term, healthy placentas and umbilical cords, all non-controversial sources of stem cells. The company’s mission does not include the use of, nor research into, embryonic or fetal stem cells, both the cause of ethical and moral concerns.
Safe Harbor Statement
This report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based on assumptions that in the future may prove not to have been accurate and are subject to risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive service and general economic risks and uncertainties.
Medistem Laboratories, Inc.
CONTACT: Neil H. Riordan, Ph.D., Chairman, President and CEO of MedistemLaboratories, Inc., +1-954-727-3662, Riordan@Medisteminc.com
